Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028574 · ClinicalTrials.gov registry record · Phase 3
Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 223
- Enrollment target
NCT00028574 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 223 participants.
The verdict
NCT00028574, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 223 participants
- Enrollment target
Study Summary
RATIONALE: Gabapentin may be effective in relieving hot flashes in men who have prostate cancer. It is not yet known which regimen of gabapentin is most effective in treating hot flashes. PURPOSE: Randomized phase III trial to compare different regimens of gabapentin in treating men who have prostate cancer.
Interventions
- OTHER placebo
- DRUG gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2001-12 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028574
The ClinicalTrials.gov registry entry for NCT00028574 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00028574 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00028574 about?
NCT00028574 is a clinical study titled "Gabapentin in Treating Hot Flashes in Patients With Prostate Cancer". RATIONALE: Gabapentin may be effective in relieving hot flashes in men who have prostate cancer. It is not yet known which regimen of gabapentin is most effective in treating hot flashes. PURPOSE: Randomized phase III trial to compare different regimens of gabapentin in treating men who have prosta...
What is the current status of trial NCT00028574?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 223 participants. The study started on 2001-12. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00028574?
The interventions under investigation include: placebo (OTHER), gabapentin (DRUG).
Who is sponsoring clinical trial NCT00028574?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.